Cargando…

Case report: Tisagenlecleucel for treatment of relapsed B- acute lymphoblastic leukemia in a patient with CHEK2 mutation

BACKGROUND: Germline Checkpoint Kinase 2 gene (CHEK2) mutations can increase the risk of solid tumors. Recently, they have been identified as risk factors for hematologic malignancies. However, to the best of our knowledge, B-acute lymphoblastic leukemia (B-ALL) has never been described as a present...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ipe, Abraham, Angiolillo, Anne, Jacobsohn, David, Cheng, Jinjun, Bornhorst, Miriam, Turner, Joyce, Vatsayan, Anant
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Pediatrics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10014590/ https://www.ncbi.nlm.nih.gov/pubmed/36937957 http://dx.doi.org/10.3389/fped.2023.1067131

Ejemplares similares

Indirect comparison of tisagenlecleucel and blinatumomab in pediatric relapsed/refractory acute lymphoblastic leukemia
por: Verneris, Michael R., et al.
Publicado: (2021)

Testicular relapse of acute lymphoblastic leukemia()
por: Carolan, Alexandra, et al.
Publicado: (2023)

CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia
por: Vairy, Stephanie, et al.
Publicado: (2018)

Tisagenlecleucel immunogenicity in relapsed/refractory acute lymphoblastic leukemia and diffuse large B-cell lymphoma
por: Thudium Mueller, Karen, et al.
Publicado: (2021)

Tisagenlecleucel: The First CAR on the Highway to Remission for Acute Lymphoblastic Leukemia
por: Freyer, Craig W.
Publicado: (2018)

Real-world use of tisagenlecleucel in infant acute lymphoblastic leukemia
por: Moskop, Amy, et al.
Publicado: (2022)

Beyond CD19: Opportunities for Future Development of Targeted Immunotherapy in Pediatric Relapsed-Refractory Acute Leukemia
por: Shalabi, Haneen, et al.
Publicado: (2015)

Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial
por: Laetsch, Theodore W., et al.
Publicado: (2023)

Relapsed Childhood Acute Lymphoblastic Leukemia: A Single-Institution Experience
por: Tuong, Pham Nguyen, et al.
Publicado: (2020)

Next-Generation Sequencing of Minimal Residual Disease for Predicting Relapse after Tisagenlecleucel in Children and Young Adults with Acute Lymphoblastic Leukemia
por: Pulsipher, Michael A., et al.
Publicado: (2022)

Short-course blinatumomab for refractory/relapse precursor B acute lymphoblastic leukemia in children
por: Xie, Jiao, et al.
Publicado: (2023)

Targeted Treatment and Immunotherapy in High-risk and Relapsed/Refractory Pediatric Acute Lymphoblastic Leukemia
por: Graiqevci-Uka, Violeta, et al.
Publicado: (2022)

Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
por: v. Stackelberg, Arend, et al.
Publicado: (2023)

Tisagenlecleucel utilisation and outcomes across refractory, first relapse and multiply relapsed B-cell acute lymphoblastic leukemia: a retrospective analysis of real-world patterns
por: Barsan, Valentin, et al.
Publicado: (2023)

Pooled safety analysis of tisagenlecleucel in children and young adults with B cell acute lymphoblastic leukemia
por: Levine, John E, et al.
Publicado: (2021)

Gene Mutations Related to Glucocorticoid Resistance in Pediatric Acute Lymphoblastic Leukemia
por: Zhang, JinFang, et al.
Publicado: (2022)

Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era
por: Mengxuan, Shang, et al.
Publicado: (2022)

Current Use of Asparaginase in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
por: Maese, Luke, et al.
Publicado: (2022)

Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a U.S. Hospital’s Perspective
por: Yang, Hongbo, et al.
Publicado: (2020)

Effectiveness of T-Cell Replete Haploidentical Hematopoietic Stem Cell Transplantation for Refractory/Relapsed B Cell Acute Lymphoblastic Leukemia in Children and Adolescents
por: Sano, Hideki, et al.
Publicado: (2021)

The relapsed acute lymphoblastic leukemia network (ReALLNet): a multidisciplinary project from the spanish society of pediatric hematology and oncology (SEHOP)
por: Velasco, Pablo, et al.
Publicado: (2023)

Epigenetic Modifications in Pediatric Acute Lymphoblastic Leukemia
por: Burke, Michael J., et al.
Publicado: (2014)

Synthesized evidence for childhood acute lymphoblastic leukemia
por: Onyije, Felix M., et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Tisagenlecleucel in the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukaemia in Children and Young Adults in Spain
por: Ribera Santasusana, Josep Maria, et al.
Publicado: (2020)

Supportive methods for childhood acute lymphoblastic leukemia then and now: A compilation for clinical practice
por: Podpeskar, Alexandra, et al.
Publicado: (2022)

FPGS relapse-specific mutations in relapsed childhood acute lymphoblastic leukemia
por: Yu, Sung-Liang, et al.
Publicado: (2020)

Mutational profiling of acute lymphoblastic leukemia with testicular relapse
por: Ding, Ling-Wen, et al.
Publicado: (2017)

Successful hematopoietic stem cell transplantation for two patients with relapse of intrachromosomal amplification of chromosome 21-positive B-cell precursor acute lymphoblastic leukemia
por: Harada, Tomoya, et al.
Publicado: (2022)

Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
por: Hall, Erin M, et al.
Publicado: (2021)

Cost-Effectiveness and Budget Impact Analyses of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia from the Singapore Healthcare System Perspective
por: Wang, Xiao Jun, et al.
Publicado: (2022)

Chemotherapy-Induced Oxidative Stress in Pediatric Acute Lymphoblastic Leukemia
por: Chaudhary, Preety, et al.
Publicado: (2023)

Assessment of the Prevalence of Infections in Pediatric Patients With Acute Lymphoblastic Leukemia
por: Nair, Arun, et al.
Publicado: (2023)

Can CD34(+)CD38(−) lymphoblasts, as likely leukemia stem cells, be a prognostic factor in B-cell precursor acute lymphoblastic leukemia in children?
por: Stolpa, Weronika, et al.
Publicado: (2023)

Correction: Tisagenlecleucel infusion in patients with relapsed/refractory ALL and concurrent serious infection
Publicado: (2021)

Perforated jejunitis in a child with acute lymphoblastic leukemia treated with pegaspargase
por: Tang, Elizabeth R., et al.
Publicado: (2018)

The Role of the Central Nervous System Microenvironment in Pediatric Acute Lymphoblastic Leukemia
por: Gossai, Nathan P., et al.
Publicado: (2017)

Prevalence of Osteopathologies in Children and Adolescents After Diagnosis of Acute Lymphoblastic Leukemia
por: Schündeln, Michael M., et al.
Publicado: (2020)

The Role of Adipose Tissue and Obesity in Causing Treatment Resistance of Acute Lymphoblastic Leukemia
por: Sheng, Xia, et al.
Publicado: (2014)

Aberrant GATA2 Activation in Pediatric B-Cell Acute Lymphoblastic Leukemia
por: Wang, Han, et al.
Publicado: (2022)

Clinical Features and Risk Factors of Severe Pneumonia in Children With Acute Lymphoblastic Leukemia
por: Liu, Chun-yan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kldbsmefmfbfpogo4k5qcfm9ae